Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM5PBLM)

Drug Name

EYP001 Drug Info

Synonyms

Vonafexor; 1192171-69-9; UNII-XG6DG6A1UN; XG6DG6A1UN; 4-chloro-5-[4-(2,6-dichlorobenzene-1-; sulfonyl)piperazin-1-yl]-1-benzofuran-2-carboxylic acid; Vonafexor [INN]; SCHEMBL1893285; Vonafexor(PLX007,EYP-001); BCP33693; EX-A4037; EYP001;EYP 001;EYP-001; HY-109197; CS-0119143; 2-Benzofurancarboxylic acid, 4-chloro-5-(4-((2,6-dichlorophenyl)sulfonyl)-1-piperazinyl)-; 4-chloro-5-[4-(2,6-dichlorophenyl)sulfonylpiperazin-1-yl]-1-benzofuran-2-carboxylic acid

Indication

Disease Entry	ICD 11	Status	REF
Non-alcoholic steatohepatitis	DB92.1	Phase 2	[1]

Cross-matching ID

PubChem CID: 67202717
CAS Number: CAS 1192171-69-9
TTD Drug ID: DM5PBLM

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Farnesoid X-activated receptor (FXR)	TTS4UGC	NR1H4_HUMAN	Agonist	[2]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Farnesoid X-activated receptor (FXR)	DTT	NR1H4	9.173	5.722	7.333	6.967

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Non-alcoholic steatohepatitis

ICD Disease Classification

DB92.1

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Farnesoid X-activated receptor (FXR)	DTT	NR1H4	5.72E-01	0.39	1.68

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	ClinicalTrials.gov (NCT03812029) Safety, Tolerability, Pharmacokinetics and Efficacy of EYP001a in Patients With Nonalcoholic Steatohepatitis (NASH). U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of ENYO Pharma.